Cargando…

Immuno-Therapy with Anti-CTLA4 Antibodies in Tolerized and Non-Tolerized Mouse Tumor Models

Monoclonal antibodies specific for cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA4) are a novel form of cancer immunotherapy. While preclinical studies in mouse tumor models have shown anti-tumor efficacy of anti-CTLA4 injection or expression, anti-CTLA4 treatment in patients with advanced c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Persson, Jonas, Beyer, Ines, Yumul, Roma, Li, ZongYi, Kiem, Hans-Peter, Roffler, Steve, Lieber, André
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3136517/ https://www.ncbi.nlm.nih.gov/pubmed/21779410 http://dx.doi.org/10.1371/journal.pone.0022303

Ejemplares similares

Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models
por: Ying, Liu, et al.
Publicado: (2011)

Treg and CTLA-4: Two intertwining pathways to immune tolerance
por: Walker, Lucy S.K.
Publicado: (2013)

Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin
por: Richter, Maximilian, et al.
Publicado: (2015)

Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
por: Lee, Hyun Tae, et al.
Publicado: (2019)

Cooperative Roles of CTLA-4 and Regulatory T Cells in Tolerance to an Islet Cell Antigen
por: Eggena, Mark P., et al.
Publicado: (2004)

CD4(+) regulatory T cells require CTLA-4 for the maintenance of systemic tolerance
por: Friedline, Randall H., et al.
Publicado: (2009)

CD4(+) regulatory T cells require CTLA-4 for the maintenance of systemic tolerance
por: Friedline, Randall H., et al.
Publicado: (2009)

CTLA-4 on thymic epithelial cells complements Aire for T cell central tolerance
por: Michelson, Daniel A., et al.
Publicado: (2022)

Role of Cellular Heparan Sulfate Proteoglycans in Infection of Human Adenovirus Serotype 3 and 35
por: Tuve, Sebastian, et al.
Publicado: (2008)

CTLA-4 expression by B-1a B cells is essential for immune tolerance
por: Yang, Yang, et al.
Publicado: (2021)

Antibody Production in Tolerant Rabbits to Mouse Lymphoma L-5178
por: Trench, C. A. H., et al.
Publicado: (1963)

Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11, and 14
por: Wang, Hongjie, et al.
Publicado: (2010)

In Vivo Hematopoietic Stem Cell Gene Therapy for SARS-CoV2 Infection Using a Decoy Receptor
por: Wang, Hongjie, et al.
Publicado: (2022)

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
por: Peggs, Karl S., et al.
Publicado: (2009)

Transplant-tolerance induction by CTLA-4Ig in liver-transplanted rats: a lesson for the treatment of autoimmune diseases?
por: Fischer, U, et al.
Publicado: (2003)

IFNγ and CTLA-4 Drive Hepatic CD4 T-Cell Tolerance and Protection From Autoimmunity in Mice
por: Krzikalla, Daria, et al.
Publicado: (2023)

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
por: Ascierto, Paolo A, et al.
Publicado: (2011)

Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
por: Karimi, Amirali, et al.
Publicado: (2021)

Flow cytometry analysis of anti-polyethylene glycol antibodies in human plasma()
por: Fang, Jia-Long, et al.
Publicado: (2020)

Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice
por: Du, Xuexiang, et al.
Publicado: (2018)

Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates
por: Costa, Maria José, et al.
Publicado: (2019)

Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy
por: Sato, Yosuke, et al.
Publicado: (2022)

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
por: Arce Vargas, Frederick, et al.
Publicado: (2018)

The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
por: Gu, Lihu, et al.
Publicado: (2019)

Indoleamine 2,3-dioxygenase and inducible nitric oxide synthase mediate immune tolerance induced by CTLA4Ig and anti-CD154 hematopoietic stem cell transplantation in a sensitized mouse model
por: Ye, Qi-Xiang, et al.
Publicado: (2017)

Overcoming physical barriers in cancer therapy
por: Beyer, Ines, et al.
Publicado: (2013)

Analysis of Epithelial and Mesenchymal Markers in Ovarian Cancer Reveals Phenotypic Heterogeneity and Plasticity
por: Strauss, Robert, et al.
Publicado: (2011)

Correction: Analysis of Epithelial and Mesenchymal Markers in Ovarian Cancer Reveals Phenotypic Heterogeneity and Plasticity
por: Strauss, Robert, et al.
Publicado: (2011)

Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies
por: Pietsch, E C, et al.
Publicado: (2017)

Prospects of HSP70 as a genetic marker for thermo-tolerance and immuno-modulation in animals under climate change scenario
por: Hassan, Faiz-ul, et al.
Publicado: (2019)

Prevalence of Inflammatory Pathways Over Immuno-Tolerance in Peripheral Blood Mononuclear Cells of Recent-Onset Type 1 Diabetes
por: Santos, Aritania Sousa, et al.
Publicado: (2022)

Long-Term Survival and Induction of Operational Tolerance to Murine Islet Allografts by Co-Transplanting Cyclosporine A Microparticles and CTLA4-Ig
por: Kuppan, Purushothaman, et al.
Publicado: (2023)

[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti–CTLA-4 antibody in a mouse model
por: Iwata, Tomomi Nakayama, et al.
Publicado: (2019)

Tolerance to rat monoclonal antibodies. Implications for serotherapy
Publicado: (1986)

Tolerance induction in mice by antibodies to T-cell epitopes
por: Laub, R, et al.
Publicado: (2002)

Safety and Tolerability of Antibody-Drug Conjugates in Cancer
por: Wolska-Washer, Anna, et al.
Publicado: (2019)

A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma
por: Maki, Robert G., et al.
Publicado: (2013)

Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis
por: Jolly, Elaine C., et al.
Publicado: (2009)

Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety
por: Seeruttun, Sharvesh Raj
Publicado: (2019)

Impact of CTLA-4 checkpoint antibodies on ligand binding and Transendocytosis
por: Williams, Cayman, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_agbt6kgf9v2k08im7aa42qqesk